Skip to main content
. 2017 Jun 29;12(6):e0178325. doi: 10.1371/journal.pone.0178325

Fig 2.

Fig 2

Fusion PET/CT image at baseline (A.Pre) and after 4 weeks of therapy with pazopanib (B.Post) in a patient with well-differentiated thyroid cancer. Post-pazopanib scan demonstrate some improvement in FDG-avid disease, although overall this patient had stable disease (Patient 6). FDG, 18F-fluorodeoxyglucose; PET, positron-emission tomography.